Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Hold Second-Quarter 2021 Sales and Earnings Conference Call on July 29

Merck to Hold Second-Quarter 2021 Sales and Earnings Conference Call on July 29

Alpine Immune Sciences

Alpine Immune Sciences Inc (NASDAQ: ALPN) has entered into a clinical trial collaboration and supply agreement with Merck & Co Inc (NYSE: MRK).  This collaboration will evaluate the safety and efficacy of Alpine's ALPN-202 in combination with Merck's Keytruda (pembrolizumab) in patients with advanced malignancies.

Alpine Immune Sciences Initiates Trial Collaboration With Merck

Merck's (MRK) Keytruda gets approval in combination with chemotherapy in first-line setting for advanced esophageal and HER2-negative GEJ cancer based on data from the phase III KEYNOTE-590 study

Merck's (MRK) Keytruda Gets Nod for Esophageal Cancer in EU

Amgen

Eli Lilly

Pfizer

We have been long-term owners of Amgen ( AMGN , Financial), Merck ( MRK , Financial) and Pfizer ( PFE , Financial) among the major pharma and biotech companies. We believe they trade at a ridiculous discount to similar companies in other industries.

Good Medicine at Bargain Prices

Bristol-Myers

Johnson & Johnson

Fierce Pharma reported RBC Capital Markets said a nearly 10% drop in biotech stocks for the first six months of the year could ignite a bonanza of second-half deals.

Merck, Johnson & Johnson and Bristol-Myers Seen as Most Active in M&A

The European Commission has approved Merck & Co Inc's (NYSE: MRK) Keytruda in combination with platinum- and fluoropyrimidine-based chemotherapy as first-line treatment of Esophageal Carcinoma or Gastroesophageal Junction (GEJ) Adenocarcinoma. The approval covers patients with locally advanced unresectable or metastatic carcinoma of the esophagus or HER2-negative GEJ adenocarcinoma whose tumors express PD-L1.

Merck's Keytruda-Chemo Combo Wins European Approval In Esophagus Cancer

MADISON, N.J., June 29, 2021 /PRNewswire/ -- Merck Animal Health, known as MSD Animal Health outside the US and Canada, a division of Merck & Co., Inc., Kenilworth, N.J.

Merck Animal Health Survey Reveals Pet Owners Need Advice Navigating Their Pets' Transition to Normalcy

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--EC Approves Merck's KEYTRUDA Plus Chemotherapy for Certain Patients With Esophageal Cancer or HER2-Negative GEJ Adenocarcinoma

European Commission Approves Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy for Certain Patients With Esophageal Cancer or HER2-Negative Gastroesophageal Junction (GEJ) Adenocarcinoma

Apple

Caterpillar

Salesforce

Cisco Systems

Goldman Sachs

Home Depot

Intel

McDonald's

Microsoft

Vaxcyte

Sio Gene Therapies

UnitedHealth Group

Visa

Two new sample breakout stocks for Week 26 with better than 10% short-term upside potential. This past week, the peak gains were in PDSB +18.6% and FSTX +6.7% with Market and S&P 500 Momentum Gauges the most negative since February.

Week 26 MDA Breakout Stocks - July 2021: Short-Term Picks To Give You An Edge

Competitors beating Merck for COVID-19 treatment. Proof of Molunupiravir efficacy is elusive.

Merck Desperate To Get Back In Coronavirus Race, With A Pill

Walgreens

If you've been bitten by the shiba inu, try investing in the type of dog that pays.

Forget Dogecoin: These Dogs of the Dow Are More Likely to Make You Rich

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Appoints Michael Klobuchar Chief Strategy Officer

Merck Appoints Michael Klobuchar Chief Strategy Officer

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--LYNPARZA® (olaparib) Approved in China for the Treatment of Certain Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

LYNPARZA® (olaparib) Approved in China for the Treatment of Certain Patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

Merck & Co, Inc. (MRK) Management Presents at Guggenheim Biopharma Strategy Series Conference Call (Transcript)

Coca-Cola

Procter & Gamble

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

While Berkshire Hathaway Inc. (NYSE: BRK-B) doesn't own most of the 30 equities in the Dow Jones Industrial Average, more than half of the eight Dow stocks that Warren Buffett and Berkshire do own are trading down year to date.

The 5 Poor Performing Dow Stocks in Warren Buffett's Portfolio

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Phase 3 KEYNOTE-826 Trial Met Dual Primary Endpoints of OS & PFS in Patients With Persistent, Recurrent or Metastatic Cervical Cancer

Merck Announces Phase 3 KEYNOTE-826 Trial Met Dual Primary Endpoints of Overall Survival (OS) and Progression-Free Survival (PFS) in Patients With Persistent, Recurrent or Metastatic Cervical Cancer

Zoetis

Zoetis stock has risen 2x from levels of $92 that it was at on March 23, 2020, when broader markets made a bottom, to levels of $184 now, while Merck's stock has underperformed and gained only 26% of its value. Looking at valuation, Merck stock trades at about 4x trailing revenues, compared.

Does The Valuation Gap Between Merck Stock And Zoetis Make Sense?

Merck/Ridgeback Bio partnership on tablet form of antiviral molnuparivir attracts US Government interest for early-stage COVID treatment.

Early-Stage Covid Treatment Prospects: Merck/Ridgeback Bio And Starpharma Lead The Pack

Thor Industries

Vertex Pharmaceuticals

Analyst 12-month price targets are the educated guesstimates that many obsess over, and can result in wild short-term price swings. According to JPMorgan, 94% of 12-month returns are luck, which is why I never base investment decisions on 12-month price targets.

3 Blue-Chip Bargains That Could Soar 20+% In The Next Year

British American Tobacco

Enterprise Products Partners

Lockheed Martin

Magellan Midstream Partners

Norsk Hydro ASA

Orange

6 Investments With 14-20% Annual Upside

U.S. government commits to purchase approximately 1.7 million courses of Molnupiravir upon issuance of Emergency Use Authorization or approval by the U.S. Food and Drug Administration KENILWORTH, N.J., June 17, 2021 /PRNewswire/ -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced it has entered into a procurement agreement with the United States government for Molnupiravir (MK-4482).

MSD Announces Supply Agreement with U.S. Government for Molnupiravir, an Investigational Oral Antiviral Candidate for Treatment of Mild to Moderate COVID-19

Coronavirus prevention goes beyond vaccines.

This Biopharma Giant May Have Just Found Its Ticket To Riches In the COVID-19 Market

AbbVie

General Motors

Sirius XM Holdings Inc

StoneCo

Suncor Energy

U.S. Bancorp

On Wednesday, we took a look at five of the 13 stocks in which Warren Buffett lightened or sold entirely Berkshire Hathaway Inc.

Warren Buffet Sold These 8 Stocks in Q1 and All Have Done Well in Q2

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Participate in the Guggenheim Biopharma Strategy Series

Merck to Participate in the Guggenheim Biopharma Strategy Series

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MERCK--Merck Announces the Kenneth C. Frazier Award for Maternal Health Equity to Accelerate Progress towards Improved Birth Outcomes for All

News for Merck Stock (MRK)